Gilead’s HIV blockbuster Truvada looks set to face generic competition in the US next year, a year earlier than expected, putting the bulk of the product’s $3 billion annual sales at risk. The biopharma leader had been predicting the onset of generic competition to Truvada in 2021, but a recent SEC filing from Gilead suggests Teva – in pole position to bring a copycat version to market – is now able to launch in 2020. Gilead is already facing competition to Truvada in Europe, where patent protection extended by a supplementary protection certificate (SPC) was overturned last year and generics have already been launched – albeit at risk of damages if Gilead were to win an appeal of the ruling. Learn More